EP1605052B1 - Procédé de production de vaccins antigrippaux polyvalents composés d'hemagglutinine - Google Patents

Procédé de production de vaccins antigrippaux polyvalents composés d'hemagglutinine Download PDF

Info

Publication number
EP1605052B1
EP1605052B1 EP05076536A EP05076536A EP1605052B1 EP 1605052 B1 EP1605052 B1 EP 1605052B1 EP 05076536 A EP05076536 A EP 05076536A EP 05076536 A EP05076536 A EP 05076536A EP 1605052 B1 EP1605052 B1 EP 1605052B1
Authority
EP
European Patent Office
Prior art keywords
influenza
hemagglutinin
signal peptide
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP05076536A
Other languages
German (de)
English (en)
Other versions
EP1605052A3 (fr
EP1605052A2 (fr
Inventor
Gale Eugene Smith
Franklin Volvovitz
Bethanie E. Wilkinson
Andrei I. Voznesensky
Craig Stanway Hackett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protein Sciences Corp
Original Assignee
Protein Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27508642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1605052(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Protein Sciences Corp filed Critical Protein Sciences Corp
Priority to DK05076536.1T priority Critical patent/DK1605052T3/da
Priority to EP11159899.1A priority patent/EP2374894B1/fr
Publication of EP1605052A2 publication Critical patent/EP1605052A2/fr
Publication of EP1605052A3 publication Critical patent/EP1605052A3/fr
Application granted granted Critical
Publication of EP1605052B1 publication Critical patent/EP1605052B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Definitions

  • the present invention is generally in the area of recombinant influenza vaccines.
  • Epidemic influenza occurs annually and is a cause of significant morbidity and mortality worldwide. Children have the highest attack rate, and are largely responsible for transmission of influenza viruses in the community. The elderly and persons with underlying health problems are at increased risk for complications and hospitalization from influenza infection. In the United States alone, more than 10,000 deaths occurred during each of seven influenza seasons between 1956 and 1988 due to pneumonia and influenza, and greater than 40,000 deaths were reported for each of two seasons (Update: Influenza Activity - United States and Worldwide, and Composition of the 1992-1993 Influenza Vaccine, Morbidity and Mortality Weekly Report._U.S. Department of Health and Human Services, Public Health Service, 41/No.
  • Influenza viruses are highly pleomorphic particles composed of two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA).
  • the HA mediates attachment of the virus to the host cell and viral-cell membrane fusion during penetration of the virus into the cell.
  • the influenza virus genome consists of eight single-stranded negative-sense RNA segments of which the fourth largest segment encodes the HA gene.
  • the influenza viruses are divided into types A, B and C based on antigenic differences. Influenza A viruses are described by a nomenclature which includes the sub-type or type, geographic origin, strain number, and year of isolation, for example, A/Beijing/353/89.
  • H1-H13 There are at least 13 sub-types of HA (H1-H13) and nine subtypes of NA (N1-N9). All subtypes are found in birds, but only H1-H3 and N1-N2 are found in humans, swine and horses ( Murphy and Webster, "Orthomyxoviruses", in Virology, ed. Fields, B.N., Knipe, D.M., Chanock, R.M., 1091-1152 (Raven Press, New York, (1990 )).
  • Antibodies to HA neutralize the virus and form the basis for natural immunity to infection by influenza ( Clements, "Influenza Vaccines", in Vaccines: New Approaches to Immunological Problems, ed. Ronald W. Ellis, pp. 129-150 (Butterworth-Heinemann, Stoneham, MA 1992 )). Antigenic variation in the HA molecule is responsible for frequent outbreaks to influenza and for limited control of infection by immunization.
  • HA glycosylated polypeptide
  • influenza HA-specific neutralizing IgG and IgA antibody is associated with resistance to infection and illness (Clements, 1992).
  • Inactivated whole virus or partially purified (split subunit) influenza vaccines are standardized to the quantity of HA from each strain.
  • Influenza vaccines usually include 7 to 25 micrograms HA from each of three strains of influenza.
  • NA major surface glycoprotein
  • Neuraminidase is very labile to the process of purification and storage (Murphy and Webster, 1990) and the quantity of NA in the current influenza vaccines is not standardized. Purified HA but not NA vaccine prevents disease in animals challenged with influenza ( Johansson, et al, "Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection" J. Virology, 63:1239-1246 (1989 )). An experimental vaccine based on neuraminidase antigen was not found to be protective in a human trial ( Orga et al, J. Infect. Dis. 135:499-506 (1977 )).
  • Licensed influenza vaccines consist of formalin-inactivated whole or chemically split subunit preparations from two influenza A subtype (H1N1 and H3N2) and one influenza B subtype viruses.
  • the U.S. Food and Drug Administration's Vaccines and Related Biologicals Advisory Committee recommends the composition of a trivalent influenza vaccine for the upcoming season.
  • the 1992-93 vaccine contained A/Texas/36/91-like(H1N1), A/Beijing/353/89-like(H3N2), and B/Panama/45/90 viruses.
  • the FDA has advised that the 1993-94 influenza vaccine should contain the same Texas and Panama strains and a new influenza A Beijing strain (A/Beijing/32/92).
  • Vaccination of high-risk persons each year before the influenza season is the most effective measure for reducing the impact of influenza.
  • Limitations of the currently available vaccines include low use rates; poor efficacy in the elderly and in young children; production in eggs; antigenic variation; and adverse reactions.
  • the Center for Disease Control estimates that less than 30% of the individuals at high-risk for influenza are vaccinated each year (MMWR, 1992).
  • the current inactivated vaccines achieve a high rate of protection against disease among normal healthy adults when the antigens of the vaccine and those of the circulating influenza viruses are closely related.
  • the rate of protection against illness is much lower, especially for those who are institutionalized (Clements, 1992).
  • significant antibody responses to a trivalent subvirion influenza vaccine were observed in less than 30 percent of subjects 65 years old or older.
  • Seed viruses for influenza A and B vaccines are naturally occurring strains that replicate to high titers in the allantoic cavity of chicken eggs.
  • the strain for the influenza A component is a reassortant virus with the correct surface antigen genes.
  • a reassortant virus is one that, due to segmentation of the viral genome, has characteristics of each parental strain. When more than one influenza viral strains infect a cell, these viral segments mix to create progeny virion containing various assortments of genes from both parents.
  • influenza vaccines Protection with current whole or split influenza vaccines is short-lived and wanes as antigenic drift occurs in epidemic strains of influenza.
  • Influenza viruses undergo antigenic drift as a result of immune selection of viruses with amino acid sequence changes in the hemagglutinin molecule.
  • the vaccine strains match the influenza virus strains causing disease.
  • the current manufacturing process for influenza vaccines is limited by propagation of the virus in embryonated chicken eggs. Not all influenza virus strains replicate well in eggs; thus the viruses must be adapted or viral reassortants constructed. Extensive heterogeneity occurs in the hemagglutinin of egg-grown influenza viruses as compared to primary isolates from infected individuals grown in mammalian cells ( Wang, et al, Virol.
  • influenza vaccines can result in a mixture of antigenically distinct subpopulations of virus.
  • the viruses in the vaccine may therefore differ from the variants within the epidemic strains, resulting in suboptimal levels of protection.
  • a method of producing an influenza vaccine that does not require propagation in eggs would result in a purer product that would be less likely to cause an adverse immune reaction.
  • a purer vaccine preparation would not require virus inactivation or organic extraction of viral membrane components, thereby avoiding denaturation of antigenic epitopes and safety concerns due to residual chemicals in the vaccine.
  • influenza vaccine produced in the absence of egg propagation would avoid the genetic heterogeneity that occurs during adaptation and passage through eggs. This would result in a vaccine that is better matched with influenza epidemic strains, resulting in improved efficacy.
  • Virus Research (1986) 5:43-59 discloses cell-surface expression of influenza virus haemagglutinin in insect cells using a baculovirus vector.
  • J. Gen. Virol (1987) 68:1233-1250 discloses the use of baculovirus vectors for the expression of the haemagglutinin gene of influenza A in Spodoptera frugiperda cells.
  • EMBO J. (1986) 5:1359-1366 discloses the expression of the influenza (fowl plague) virus haemagglutinin in S. frugiperda cells by a baculovirus vector, and immunization of chickens with S. frugiperda cells expressing the haemagglutinin.
  • EP0546787 discloses the expression in a baculovirus system in Sf9 cells of a 1.75 kb haemagglutinin sequence or a chimeric protein comprising HIV epitopes inserted into the haemagglutinin gene.
  • Virology (1994) 202:586-605 discloses the complete DNA sequence of the baculovirus Autographa californica nuclear polyhedrosis virus (AcNPV).
  • the present invention provides a method for making a hemagglutinin fusion protein, a method for making a vector, a recombinant influenza hemagglutinin fusion protein and a vaccine composition as defined in the appended claims.
  • a method of preparing a recombinant influenza hemagglutinin protein by expression in insect cells using a baculovirus expression system is provided.
  • the resulting protein is useful in making a multivalent influenza vaccine based on a mixture of recombinant haemagglutinin antigens cloned from influenza viruses having epidemic potential.
  • the recombinant hemagglutinin proteins are full length, uncleaved (HA0) glycoproteins including both the HA1 and HA2 subunits (HA0) purified under non-denaturing conditions to 95% or greater purity, preferably 99% purity.
  • a process for cloning influenza hemagglutinin genes from influenza A and B viruses using specially designed oligonucleotide probes and polymerase chain reaction (PCR) methodology is also disclosed.
  • the cloned HA genes are modified by deletion of the nucleotides encoding the natural hydrophobic signal peptide sequences and replacement with a new baculovirus signal peptide, to yield a sequence encoding the signal peptide immediately abutting the hemagglutinin.
  • These chimeric genes are introduced into baculovirus expression vectors so that the baculovirus polyhedrin promoter directs the expression of recombinant HA proteins in infected insect cells.
  • the 18 amino acid baculovirus signal peptide directs the translation of rHA into the insect cell glycosylation pathway and is not present on the mature rHA glycoprotein.
  • a vector is designed that does not encode any intervening amino acids between the signal peptide and hemagglutinin protein.
  • This methodology can be extended to all types of influenza viruses, including but not limited to the prevalent A (H1N1) sub-type, the A(H3N2) sub-type, and the B type that infect humans, as well as the influenza viruses which infect other mammalian and avian species.
  • a general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is disclosed for the purification of rHA proteins from A sub-types and B type influenza viruses.
  • the recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. This allows rapid development of vaccine directly from epidemic strains of influenza and avoids the problems arising from adaptation of the virus for culture in eggs, as well as patient reaction to egg contamination in the resulting vaccine.
  • Examples demonstrate the formulation and clinical efficacy of vaccine in an immunizing dosage form including purified rHA antigens from three strains of influenza virus recommended by the FDA for the 1993/1994 and 1994/1995 influenza epidemic seasons. Functional immunity was measured using assays that quantitate antibodies that bind to influenza hemagglutinin, that block the ability of influenza virus to agglutinate red blood cells, or that neutralize the influenza virus. Protective immune responses with rHA vaccines were measured in animals that are susceptible to influenza infection or in human challenge studies.
  • a method of preparing a recombinant influenza vaccine is described.
  • a full length, uncleaved (HA0), hemagglutinin antigen from an influenza virus is produced with baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions.
  • Two or more purified hemagglutinin antigens from influenza A and/or influenza B strains are mixed together to produce a multivalent influenza vaccine.
  • the recombinant antigens may be combined with an adjuvant carrier for increased efficacy.
  • a recombinant DNA influenza vaccine can be produced under safer and more stringently controlled conditions; propagation with infectious influenza in eggs is not required; recombinant HA protein can be more highly purified, virtually eliminating side effects due to contaminating proteins; purification procedures for recombinant HA do not have to include virus inactivation or organic extraction of viral membrane components, therefore avoiding denaturation of antigens and additional safety concerns due to residual chemicals in the vaccine; production of HA via recombinant DNA technology provides an opportunity to avoid the genetic heterogeneity which occurs during adaptation and passage through eggs, which should make it possible to better match vaccine stains with influenza epidemic stains, resulting in improved efficacy; and a recombinant approach may also allow for strain selection later in the year, thereby allowing time for selections based on more reliable epidemiological data.
  • Baculoviruses are DNA viruses in the family Baculoviridae. These viruses are known to have a narrow host-range that is limited primarily to Lepidopteran species of insects (butterflies and moths).
  • the baculovirus Autographa californica Nuclear Polyhedrosis Virus (AcNPV) which has become the prototype baculovirus, replicates efficiently in susceptible cultured insect cells.
  • AcNPV has a double-stranded closed circular DNA genome of about 130,000 base-pairs and is well characterized with regard to host range, molecular biology, and genetics.
  • baculoviruses including AcNPV
  • a single polypeptide referred to as a polyhedrin
  • the gene for polyhedrin is present as a single copy in the AcNPV viral genome. Because the polyhedrin gene is not essential for virus replication in cultured cells, it can be readily modified to express foreign genes. The foreign gene sequence is inserted into the AcNPV gene just 3' to the polyhedrin promoter sequence such that it is under the transcriptional control of the polyhedrin promoter.
  • Recombinant baculoviruses that express foreign genes are constructed by way of homologous recombination between baculovirus DNA and chimeric plasmids containing the gene sequence of interest. Recombinant viruses can be detected by virtue of their distinct plaque morphology and plaque-purified to homogeneity.
  • Baculoviruses are particularly well-suited for use as eukaryotic cloning and expression vectors. They are generally safe by virtue of their narrow host range which is restricted to arthropods.
  • the U.S. Environmental Protection Agency (EPA) has approved the use of three baculovirus species for the control of insect pests.
  • AcNPV has been applied to crops for many years under EPA Experimental Use Permits.
  • AcNPV wild type and recombinant viruses replicate in a variety of insect cells, including continuous cell lines derived from the fall armyworm, Spodoptera frugiperda (Lepidoptera; Noctuidae). S. frugiperda cells have a population doubling time of 18 to 24 hours and can be propagated in monolayer or in free suspension cultures.
  • Recombinant HA proteins can be produced in, but not limited to, cells derived from the Lepidopteran species Spodoptera frugiperda.
  • Other insect cells that can be infected by baculovirus, such as those from the species Bombix mori, Galleria mellanoma, Trichplusia ni, or Lamanthria dispar, could also be used as a suitable substrate to produce recombinant HA proteins.
  • the most preferred host cell line for protein production from recombinant baculoviruses is Sf900+.
  • Another preferred host cell line for protein production from recombinant baculoviruses is Sf9.
  • Sf900+ and Sf9 are non-transformed, non-tumorigenic continuous cell lines derived from the fall armyworm, Spodoptera frugiperda (Lepidoptera; Noctuidae).
  • Sf900+ and Sf9 cells are propagated at 28 ⁇ 2°C without carbon dioxide supplementation.
  • the culture medium used for Sf9 cells is TNMFH, a simple mixture of salts, vitamins, sugars and amino acids, supplemented with 10% fetal bovine serum.
  • Serum free culture medium available as Sf900 culture media, Gibco BRL, Gaithersburg, MD
  • Sf900 culture media can also be used to grow Sf9 cells and is preferred for propagation of Sf900+ cells.
  • Sf9 cells have a population doubling time of 18-24 hours and can be propagated in monolayer or in free suspension cultures.
  • S. frugiperda cells have not been reported to support the replication of any known mammalian viruses.
  • the expression vector is not limited to a baculovirus expression system.
  • the recombinant HA proteins can also be expressed in other expression vectors such as Entomopox viruses (the poxviruses of insects), cytoplasmic polyhedrosis viruses (CPV), and transformation of insect cells with the recombinant HA gene or genes constitutive expression.
  • Entomopox viruses the poxviruses of insects
  • CPV cytoplasmic polyhedrosis viruses
  • influenza strains are isolated from individuals infected with the disease.
  • the influenza strains are those identified by the Food and Drug Administration (FDA) or CDC to have epidemic potential for the subsequent influenza season.
  • FDA Food and Drug Administration
  • An advantage of the method described herein is that clinical samples, such as nasal secretions, from patients infected with influenza can be used as a direct source of virus. Alternatively, they can be obtained from the FDA or CDC.
  • MDCK Madin Darby Canine Kidney
  • TPCK tosylphenylalanyl chloromethylketone
  • the MDCK cells are infected with the influenza strains at a low multiplicity of infection (0.1 to 0.5) as determined by a standard HA assay ( Rosen, "Hemagglutination with Animal Viruses” in Fundamental Techniques in Virology, ed. K. Habel and N.P.
  • Viral particles produced from the first passage are purified from the media using a known purification method such as sucrose density gradient centrifugation.
  • a known purification method such as sucrose density gradient centrifugation.
  • virus is harvested 24-48 hours post infection by centrifuging media of influenza infected MDCK cells.
  • the resulting viral pellet is resuspended in buffer and centrifuged through a buffered sucrose gradient.
  • the influenza virus band is harvested from the 40-45% sucrose region of the gradient, diluted with buffer and pelleted by centrifugation at 100,000 x g.
  • the purified virus pellet is resuspended in buffer and stored at - 70°C.
  • FIG. 1 An overview of the methods for cloning HA genes is provided in Figure 1 .
  • Virus is harvested from the cell media and either viral RNA, for Influenza A strains, or mRNA, for Influenza B strains, is isolated.
  • Viral RNA (-RNA) is extracted from purified virions and analyzed on formaldehyde agarose gels using standard procedures, cDNA is synthesized, using either an universal primer system for the viral RNA from the Influenza A strains or random primers for the mRNA from Influenza B strains.
  • cDNA Plus-standard complimentary DNA
  • cDNA is made using a universal oligonucleotide primer (5'-AGCAAAAGCAGG-3' (SEQ ID NO. 1)) which is homologous to all hemagglutinin RNA segments in influenza A and B viruses ( Davis et al, "Construction and characterization of a bacterial clone containing the hemagglutinin gene of the WSN strain (H0N1) of influenza virus” Gene, 10:205-218 (1980 )).
  • Primers are designed that are homologous to conserved regions at the 5' and 3' end of influenza hemagglutinin genes. Both 5' and 3' primers also have restriction enzyme sites at the ends that are not found within the haemagglutinin genes.
  • influenza A or B primers and influenza cDNA are mixed and the hemagglutinin gene segments amplified using standard PCR procedures.
  • the resulting double-stranded DNA fragments contain entire mature hemagglutinin coding sequences.
  • the polymerase chain reaction ("PCR") is used to amplify the total HA gene, which is then cloned into a suitable bacterial host such as E. coli.
  • the 5' ends are sequenced to identify the signal peptide of the HA genes, then PCR is used to amplify the HA genes minus the signal peptide. This is then subcloned into a plasmid transfer vector containing the AcNPV polyhedrin promoter.
  • the resulting transfer vectors contain the following 5'->3' sequences: Polyhedrin promoter from the baculovirus A . californica NPV, an ATG translational start codon, a 61K baculovirus signal peptide, the coding sequences for mature hemagglutinin, the natural hemagglutinin translational termination codon, the polyhedrin RNA polyadenylation signal, and flanking baculovirus DNA.
  • a purified chimeric transfer plasmid DNA containing a cloned hemagglutinin gene is then mixed with AcNPV wild type DNA, co-precipitated with calcium and transfected into S. frugiperda cells.
  • Recombinant baculoviruses are selected on the basis of plaque morphology and further purified by additional rounds of plaque-purification. Cloned recombinant baculoviruses are screened for hemagglutinin expression and a single baculovirus expression vector is selected to produce a Master Virus Bank.
  • HA genes from influenza A strains are cloned from purified viral RNA preparations.
  • Viral RNA is extracted from 100-200 microliters of purified influenza A virions containing 1,000-2,000 hemagglutination units (HAU) of influenza.
  • HAU hemagglutination units
  • One HAU is the amount of virus that will agglutinate 50% of the red blood cells in the standard agglutination assay (Rosen, 1969).
  • the virions are treated with proteinase K to digest protein, then the viral RNA is extracted with equal volumes of phenol and chloroform, and precipitated with ethanol in the presence of tRNA carrier.
  • RNA is resuspended in buffer and digested with RNAse-free DNAse to remove any contaminating DNA, then the extraction and precipitation steps repeated.
  • Viral RNA (vRNA) is then analyzed using formaldehyde agarose gels as described by Maniatis, et al. Molecular Cloning: A Laboratory Manual. pp. 86-96 and 366-367 (Cold Spring Harbor Lab., Cold Spring, N.Y. 1982 ).
  • HA genes from influenza B strains are cloned from total messenger RNA (mRNA) extracted from cells infected with the influenza B-strain. Total RNA is then extracted from the infected cells. The harvested cells are lysed in the presence of guanidinium thiocyanate and total cell RNA is purified, using, for example, the RNA Extraction Kit from Pharmacia Biotech Inc. (Piscataway, NJ) Total mRNA is extracted from cellular RNA using Oligo-(dT)-cellulose spun columns, using, for example, the mRNA Purification Kit from Pharmacia Biotech Inc.
  • Recombinant hemagglutinin antigens are expressed at high levels in S. frugiperda cells infected with AcNPV-hemagglutinin vectors.
  • the primary gene product is unprocessed, full length hemagglutinin (rHA0) and is not secreted but remains associated with peripheral membranes of infected cells.
  • This recombinant HA0 is a 68,000 molecular weight protein which is glycosylated with N-linked, high-mannose type glycans distinct from the glycans produced by expression of the viral proteins in mammalian or avian cells. There is evidence that rHA0 forms trimers post-translationally which accumulate in cytoplasmic membranes.
  • HAO is a better vaccine due to its superior stability as compared to the HA1/HA2 complex, and maintains correct folding during purification and storage.
  • the superior stability is particularly apparent with the B strains, resulting in titers that are about five fold greater than obtained with commercially available attenuated B strains.
  • the HA mature signal peptide was removed and replaced with the baculovirus chitinase signal peptide, referred to as the 61 kD signal peptide. Since the HA gene is connected to the chitinase signal peptide through a cleavage site, there are between three and five amino acids, depending on the restriction site selected, between the mature HAO protein and the 61 kD signal peptide. Although not a problem with the A strains of influenza, the B strain HAO expressed with the additional amino acids did not fold properly.
  • the first is to use a new vector, pMGS3, which does not encode the 61 kD signal peptide.
  • HAO with its native signal peptide is cloned into the vector and expressed.
  • B strain HAO expressed in this vector shows better glycosylation and processing than when expressed in pMGS12.
  • the HAO folded so well that it can be quantitatively converted to HA1/HA2.
  • the yield is not as high.
  • the second method increases the yield by using the 61 kD signal peptide in pMGS12 to guide expression where the HAO gene was inserted without the use of restriction enzymes.
  • the new vector, including the 61 kD signal peptide and HAO gene, without sequence encoding extraneous intervening amino acids, is referred to as pMGS27.
  • pMGS27 can be used for cloning and expression of any gene in a baculovirus expression system.
  • the target gene instead of being cloned into the vector by restriction and ligation, is cloned into the vector by annealing.
  • Reagents are available from Clontech in their PCR-direct Cloning System.
  • pMGS27 was designed so that it can be linearized at the end of the chitinase signal peptide coding region, and two long single-stranded tails created by treating the linearized pMGS27 with T4 DNA polymerase plus dATP.
  • the target gene is amplified using polymerase chain reaction (“PCR”) or reverse transcriptase-PCR (“RT-PCR”) with a pair of oligonucleotides designed to create single-stranded tails that are complementary to the tails of the treated pMGS27, after the PCR fragment has been treated with T4 DNA polymerase and dTTP.
  • PCR polymerase chain reaction
  • RT-PCR reverse transcriptase-PCR
  • a simple annealing can then combine the two molecules into a circular plasmid which is ready to transform the host.
  • the pMGS27 has the important advantage that it does not yield extra amino acids encoded by the restriction sites created between the chitinase signal peptide and the mature HA protein. These extra amino acids can sometimes create difficulties such that signal peptidase cannot cleave the signal or that the encoded protein does not fold correctly, as in the case of the B strain HA.
  • rHA0 can be selectively extracted from the peripheral membranes of AcNPV-hemagglutinin infected cells with a non-denaturing, nonionic detergent or other methods known to those skilled in the art for purification of recombinant proteins from insect cells, including, but not limited to affinity or gel chromatography, and antibody binding.
  • the detergent soluble rHA0 can be further purified using DEAE ion exchange and lentil lectin affinity chromatography, or other equivalent methods known to those skilled in the art.
  • the rHAO is purified using a procedure that is more gentle and results in higher yield of the rHAO from B strains of influenza. This procedure is generally as follows:
  • the HAO protein which forms an integral part of the membrane of the insect cells is separated from the soluble proteins, the peripheral membrane proteins and the majority of the DNA and RNA by extraction of the cells in a relatively viscous alkaline solution, where an alkaline pH is defined as between about 9.5 and 10.5. Viscosity is increased through the inclusion of sucrose in a concentration of approximately 250 mM.
  • a disulfide-reducing agent for example, ⁇ -mercaptoethanol, is included in a concentration effective to prevent disulfide linking of proteins in the mixture.
  • the cells are suspended in the extraction buffer, homogenized, and then centrifuged.
  • the pellet is washed by homogenization in a low ionic strength buffer containing a disulfide-reducing agent at an alkaline pH (conductivity is generally less than 1 mS, pH 10.5) and the pellet centrifuged.
  • the HAO is then extracted from the pellet in a buffer containing between 0.3 and 1.5% detergent such as Triton, an amount of disaggregating agent effect to prevent complex formation due to charge interactions, such as between 0.3 and 1.0 M betaine or paurine, at an alkaline pH (9.5 is preferred).
  • the HAO in the supernatant is then purified by anion exchange chromatography followed by cation exchange chromatography.
  • the HAO is applied to the anion exchange column, for example, DEAE or Q-Sepharose ® (an agarose bead column with quaternary amine groups), in the same buffer as extracted but diluted at least 1:2 with additional buffer, after equilibration of the column in buffer containing approximately 1/10th the concentration of detergent and disulfide-reducing agent.
  • the HAO is then eluted by lowering the pH to approximately 8.5.
  • the eluted HAO is applied to a cation exchange column in essentially the same buffer. Contaminants are eluted by lowering the pH to approximately 7.4, then eluting the HAO by increasing the salt concentration to 0.15 M NaCl.
  • Recombinant HA expressing cells (6.2 g of cells from 0.34 L of culture) are suspended at 100 mg/mL in ice-cold 100 mM sodium pyrophosphate, 100 mM sodium chloride, 250 mM sucrose, 0.1% ⁇ -mercaptoethanol, pH 10.5.
  • the cells are disrupted using a Polytron ® homogenizer (Brinkman Instruments Inc., Westbury, NY) at a setting of 4 for 2 min. Alkaline pH of the homogenization medium is needed to increase the solubility of the contaminating proteins and to increase the purity of the membrane preparation.
  • the homogenate is centrifuged for 30 min. at 9,200 g.
  • the supernatant is discarded and the pellet collected.
  • Preparation of the membrane fraction is followed by a low-ionic strength wash step.
  • the pellet is resuspended to the original volume in the ice-cold 0.1% ⁇ -mercaptoethanol, 10.5, and homogenized using a Polytron ® homogenizer at a setting of 4 for 2 min.
  • the homogenate is centrifuged for 30 min. at 9,200 g.
  • the supernatant is discarded and the pellet collected.
  • This low-ionic strength wash removes additional portion of the peripheral membrane proteins.
  • the preparation of the membrane fraction results in the considerable enrichment in the recombinant HA and in the removal of contaminating nucleic acids.
  • the recombinant HA is then selectively extracted from the membrane pellet under conditions that do not denature the antigen.
  • the membrane pellet is homogenized in 41 mL of ice-cold 10 mM ethanolamine pH 9.5, 1% Triton N101, 0.1% ⁇ -mercaptoethanol, 25 mM NaCl, 400 mM betaine using a Polytron homogenizer at a setting of 4 for 2 min. After incubation for 40 min. at 23°C, the mixture is centrifuged for 30 min. at 9,200 g. The supernatant containing recombinant HA is decanted and diluted two-fold with the same buffer.
  • Proteins are analyzed by SDS polyacrylamide gel electrophoresis. Samples are disrupted in a boiling water bath for 10 minutes in the presence of 2% sodium dodecyl sulfate (SDS) and 5% ⁇ -mercaptoethanol, then electrophoresed on an 11% polyacrylamide gel in the presence of 0.1% SDS, then stained with Coomassie blue.
  • SDS sodium dodecyl sulfate
  • Chromatographic purification Chromatographic purification of the recombinant HA was simplified and expensive affinity chromatography on Lentil Lectin Sepharose was eliminated from the process by substitution with a two-step chromatographic purification process which results in a highly purified recombinant HA antigen that is non-denatured and suitable as a component of an influenza vaccine for human use.
  • the chromatography gel matrices used are Pharmacia Q-Sepharose ® Fast Flow and CM-Sepharose Fast Flow ® .
  • Partially purified recombinant HA is then eluted with 30 mM diethanolamine pH 8.5, 0.1% Triton ® N101, 0.01% ⁇ -mercaptoethanol, 25 mM NaCl, 400 mM betaine.
  • the detergent is then removed by washing the column with 10 mM sodium phosphate pH 7.4, 10 mM NaCl until the UV absorbance of the effluent returned to the baseline.
  • Purified recombinant HA is eluted with phosphate buffer saline, pH 7.5 (PBS).
  • Purified rHA0 is resuspended in an isotonic, buffered solution. Following the removal of the detergent, purified rHA0 will efficiently agglutinate red blood cells.
  • rHA0 is purified to at least 95% purity, more preferably 99% purity. This migrates predominantly as a single major polypeptide of 68,000 molecular weight on an SDS-polyacrylamide gel.
  • the quaternary structure of purified recombinant HA0 antigen was examined by electron microscopy, trypsin resistance, density sedimentation analysis, and ability to agglutinate red blood cells. These data show that recombinant HA0 forms trimers, which assemble into rosettes.
  • Purified rHA0 does not agglutinate cells prior to removal of detergent, suggesting that the antigen must form complexes (rosettes) in order to cross-link chicken red blood cells.
  • the quantitative ability of purified rHA0 to agglutinate cells is used as a measure of lot-to-lot consistency of the antigen.
  • One hemagglutinin unit is defined as the quantity of antigen required to achieve 50% agglutination in a standard hemagglutinin assay with chicken red blood cells. Comparative data shows that purified rHA0 antigens agglutinate red blood cells with an efficiency comparable to that observed with whole influenza virions.
  • the recombinant HA0 can be cleaved at the disulfide bond, causing a conformation change that results in the formation of two chains, HA1 and HA2 as described by Carr, C.M. and Kim, P.S., "A Spring-loaded Mechanism for the Conformational Change of Influenza Hemagglutin", Cell 73:823-832 (1993 ). Cleavage of recombinant HA0 is described in more detail below in Example 6. It is believed that, upon cleavage of natural HA0 into HA1 and HA2, the chains become infectious by acquiring the ability to fuse with a cell, thereby creating an improved immune response.
  • antigens such as influenza hemagglutin occurs by the binding of antigenic peptides to major histocompatibility (MHC) molecules.
  • MHC major histocompatibility
  • the antigen/MHC complex is recognized by T cells to initiate an immune response as described in the review by Harding and Geuze, Current Opinion in Cell Biology 5:596-605 (1993 ), which is incorporated by reference herein.
  • the rHAO produced in a baculovirus is highly stable and immunogenic as the intact molecule. Comparison of the sugar molecules on the HAO expressed in insect cells shows that the glycans are different from those when the HAO is expressed in mammalian or avian cells.
  • Fusion proteins consisting of the HAO fused to a second antigenic protein can be made where the antigenicity of the second protein is low or there are advantages to eliciting an immunogenic response to multiple antigens.
  • An example of a preferred second antigen is the neuraminidase produced by influenza.
  • the antigen can consist of a cellular, viral, or bacterial protein, or antigenic portion thereof including at least five to eight amino acids.
  • Other antigens include hepatitis B antigen, HIV antigens, and carcinoembryonic antigen.
  • an “immune response”, as used herein, refers to either a humoral response, measured by the production of antibody to the antigen, or a cellular response, measured by the elicitation of a T cell mediated response to the antigen.
  • a "linker" of non-antigenic amino acids may be inserted between the HA and the antigen, to further enhance antigenicity of the antigen as compared to the HA.
  • the process involves constructing a DNA plasmid for fusing target antigen genes to full-length or fragments of the influenza virus HA gene, using oligonucleotide probes and polymerase chain reaction (PCR) methodology.
  • the HA-target antigen fusion genes are modified for proper expression in insect cells by deletion of the natural hydrophobic signal peptide sequences and replacement with a new baculovirus signal peptide.
  • the fusion gene is introduced into a baculovirus expression vector so that the baculovirus polyhedron promoter directs the transcription of the fusion proteins in infected insect cells.
  • the 18 amino acid baculovirus signal peptide directs the translation of the HA-target antigen fusion polypeptide into the insect cell glycosylation pathway and is not present on the mature fusion protein.
  • Plasmid pA9440 which contains the A/Beijing/32/92 strain HA gene in the pMGS12 baculovirus transfer plasmid described below, was used as a template for the amplification of the HA gene by polymerase chain reaction (PCR) using the protocol recommended by the supplier (Gene Amp PCR cloning kit, Perkin Elmer Cetus).
  • the PCR reaction mixture (100 ⁇ l) contained 20 pmol of primers designed to anneal to portions of the HA gene.
  • the 5' and 3' primers were designed with restriction endonuclease sites at the ends that are not found within the HA gene.
  • the 5' PCR primer (O-567) for the HA0 and HA1 fragments begins 52 base pairs downstream from the 5' end of the natural HA gene coding sequences, deleting the natural signal peptide sequence, and adds a Sma I site immediately 5' to the HA coding sequences.
  • the 5' PCR primer (O-651) for the HA2 fragment begins at nucleotide 1108 of the natural HA gene, immediately following the codon encoding the arginine residue that is removed during cleavage of HA0 to HA1 and HA2.
  • the 3' PCR primer (O-680) for the HA0 and HA2 fragments was designed to add a KpnI site immediately following the HA coding sequences, removing the natural stop codon.
  • the 3' PCR primer for HA1 (O-679) truncates the gene immediately prior to the arginine residue removed during HA0 cleavage. Amplification of the HA gene fragment was carried out for 30 cycles each consisting of 1 min. at 94°C for denaturation, 2 min. at 55°C for annealing of the primers, and 2 min. at 72°C for extension.
  • HA gene fragments were electrophoresed on agarose gels, purified from the gel using a GeneClean kit (Bio 101, Inc.), and ligated into a plasmid designed to accept PCR-generated fragments (pCRII; Invitrogen).
  • plasmids pB142, pB144, and pB330 which contain the HA0, HA1, or HA2 gene fragments, respectively, were obtained.
  • the HA gene fragments were removed from plasmids pB142, pB144, and pB330 with Sma I and Kpn I restriction enzymes and then subcloned by standard recombinant DNA techniques (Sambrook et al ., 1989) into the AcNPV transfer plasmid pMGS12.
  • the pMGS12 plasmid contains, from 5' to 3', the AcNPV polyhedron promoter, an ATG initiation codon, the sequence for a cleavable signal peptide from a 61,000 molecular weight baculovirus glycoprotein (61K), Sma I and Kpn I restriction enzyme cloning sites, and a TAA universal stop codon sequence.
  • Flanking these regulatory regions is DNA from the EcoRI I fragment from the AcNPV genome ( Summers and Smith, "A manual of methods for baculovirus vectors and insect cell culture procedures". Texas Agricultural Experimental Station Bulletin No. 1555 (1987 ).
  • the cloned HA PCR fragments were excised from the pCRII cloning vector with Sma I and Kpn I, purified with agarose gel electrophoresis and the GeneClean kit, and ligated into pMGS12 that had also been digested with Sma I and Kpn I.
  • the pB879, pB1201, and pB1205 AcNPV transfer plasmids may be used to fuse HA0 HA1, or HA2 to any gene of interest.
  • the second step in the construction of HA-CEA fusion gene transfer plasmids was to insert the CEA coding sequences into the HA-encoding constructs. Restriction endonuclease recognition/cleavage sites for Sma I and Kpn I were placed at both ends of the CEA gene through PCR amplification of plasmid pA9080.
  • the 5' PCR primer, O-649 begins 82 base pairs from the 5' end of the gene, deleting the natural CEA signal peptide sequence.
  • the 3' PCR primer, O-650 was designed to delete the last 72 basepairs at the 3' end of the gene which codes for the hydrophobic C-terminal region sequence.
  • Amplification of the CEA gene fragment was carried out for 30 cycles, each consisting of 1 min. at 94°C for denaturation, 2 min. at 55°C for reannealing, and 2 min. at 72°C for extension.
  • the resulting amplified CEA gene fragment was electrophoresed on an agarose gel, purified with the GeneClean procedure, and ligated into pCRII (Invitrogen) according to the manufacturers' instructions.
  • the resulting plasmid, pB806 contains the CEA gene without its natural signal peptide, C-terminal hydrophobic domain, or stop codon, but with both Sma I and Kpn I sites at both ends of the gene.
  • a large-scale plasmid prep was performed with the pB806 plasmid, and the DNA was digested either with Sma I or Kpn I.
  • the CEA-encoding fragments were purified with agarose gel electrophoresis and the GeneClean kit, and the purified fragments were ligated into each of the three HA-encoding constructs (pB879, pB1201, or pB1205) digested with the same restriction enzyme.
  • CEA-encoding fragments with Sma I-cut ends were ligated into the HA0-, HA1-, and HA2-encoding constructs (pB879, pB1201, and pB1205, respectively) cut with Sma I to create plasmids pB1250, pB1555, and pB1584, respectively.
  • CEA-encoding fragments with Kpn I-cut ends were ligated into the HA0-, HA1-, and HA2-encoding constructs cut with KpnI to create pB1264, pB1564, and pB1593. Insertion of the CEA gene at the Sma I site placed the CEA coding sequences downstream of the HA coding sequences.
  • the PCR primer were designed such that the EA gene was inserted in-frame with HA, and the fusion gene translation would be terminated at the universal translation termination signal (TAATTAATTAA) (Sequence ID No. 4) in the pMGS12 vector sequences downstream of the Kpn I site.
  • TAATTAATTAA universal translation termination signal
  • This construct may be improved by deletion of intervening amino acids, either between the signal peptide and HAO, as described below, or between the HAO and the fusion gene, to enhance folding and immunogenicity.
  • the rHA can be formulated and packaged, alone or in combination with other influenza antigens, using methods and materials known to those skilled in the art for influenza vaccines.
  • HA proteins from two A strains and one B strain are combined to form a multivalent vaccine.
  • the HAs are combined with an adjuvant, in an amount effective to enhance the immunogenic response against the HA proteins.
  • an adjuvant widely used in humans has been alum (aluminum phosphate or aluminum hydroxide).
  • new chemically defined preparations such as muramyl dipeptide, monophosphoryl lipid A, phospholipid conjugates such as those described by Goodman-Snitkoff et al. J. Immunol.
  • encapsulation of the protein within a proteoliposome as described by Miller et al., J. Exp. Med. 176:1739-1744 (1992 ) and encapsulation of the protein in lipid vesicles such as NovasomeTM lipid vesicles (Micro Vescular Systems, Inc., Nashua, NH) should also be useful.
  • the vaccine is packaged in a single dosage for immunization by parenteral (i.e., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (i.e., intranasal) administration.
  • parenteral i.e., intramuscular, intradermal or subcutaneous
  • nasopharyngeal i.e., intranasal
  • the effective dosage is determined as described in the following examples.
  • the carrier is usually water or a buffered saline, with or without a preservative.
  • the antigen may be lyophilized for resuspension at the time of administration or in solution.
  • the carrier may also be a polymeric delayed release system.
  • Synthetic polymers are particularly useful in the formulation of a vaccine to effect the controlled release of antigens.
  • An early example of this was the polymerization of methyl methacrylate into spheres having diameters less than one micron to form so-called nano particles, reported by Kreuter, J., Microcapsules and Nanoparticles in Medicine and Pharmacology, M. Donbrow (Ed). CRC Press, p. 125-148 .
  • the antibody response as well as the protection against infection with influenza virus was significantly better than when antigen was administered in combination with aluminum hydroxide. Experiments with other particles have demonstrated that the adjuvant effect of these polymers depends on particle size and hydrophobicity.
  • Microencapsulation has been applied to the injection of microencapsulated pharmaceuticals to give a controlled release.
  • a number of factors contribute to the selection of a particular polymer for microencapsulation.
  • the reproducibility of polymer synthesis and the microencapsulation process, the cost of the microencapsulation materials and process, the toxicological profile, the requirements for variable release kinetics and the physicochemical compatibility of the polymer and the antigens are all factors that must be considered.
  • useful polymers are polycarbonates, polyesters, polyurethanes, polyorthoesters and polyamides, particularly those that are biodegradable.
  • PLGA poly (d,l-lactide-co-glycolide)
  • PLGA poly (d,l-lactide-co-glycolide)
  • This is a biodegradable polyester that has a long history of medical use in erodible sutures, bone plates and other temporary prostheses, where it has not exhibited any toxicity.
  • a wide variety of pharmaceuticals including peptides and antigens have been formulated into PLGA microcapsules.
  • a body of data has accumulated on the adaptation of PLGA for the controlled release of antigen, for example, as reviewed by Eldridge, J.H., et al. Current Topics in Microbiology and Immunology. 1989, 146: 59-66 .
  • the entrapment of antigens in PLGA microspheres of 1 to 10 microns in diameter has been shown to have a remarkable adjuvant effect when administered orally.
  • the PLGA microencapsulation process uses a phase separation of a water-in-oil emulsion.
  • the compound of interest is prepared as an aqueous solution and the PLGA is dissolved in a suitable organic solvents such as methylene chloride and ethyl acetate. These two immiscible solutions are co-emulsified by high-speed stirring.
  • a non-solvent for the polymer is then added, causing precipitation of the polymer around the aqueous droplets to form embryonic microcapsules.
  • the microcapsules are collected, and stabilized with one of an assortment of agents
  • PVD polyvinyl alcohol
  • PVP polyvinylpyrrolidone
  • Example 1 Propagation and Purification of Influenza Viruses.
  • influenza vaccine strains were obtained from the FDA in chicken egg allantoic fluid:
  • MDCK cells were infected in the presence of TPCK-treated trypsin (Sigma Chemical Co., St. Louis, MO) and fetal bovine serum concentrations optimized to produce the highest titers of first passage virus.
  • the MDCK cells were infected with the influenza strains at a low multiplicity of infection (0.1 to 0.5) as determined by a standard HA assay ( Rosen, "Hemagglutination with Animal viruses” in Fundamental Techniques in Virology, ed. K. Habel and N.P. Salzman, pp. 276-28 (Academic Press, New York 1969 )).
  • Rosen Rosen, "Hemagglutination with Animal viruses” in Fundamental Techniques in Virology, ed. K. Habel and N.P. Salzman, pp. 276-28 (Academic Press, New York 1969 )
  • the infected cells were incubated at 33°C for 48 h.
  • TPCK trypsin and fetal bovine serum were used to prepare large stocks of influenza virus.
  • the optimum concentrations of TPCK trypsin and fetal bovine serum for the above influenza viruses are listed in Table 1. Table 1. Optimum Concentration of TPCK Trypsin and Fetal Bovine Serum. A/Beijing/ 353/89 A/Beijing/ 32/92 A/Texas/ 36/91 B/Panama /45/90 % Fetal Bovine Serum 0.25% 0.25% 0.25% 5.0% Amount TPCK Treated Trypsin 45 ⁇ /ml 45 ⁇ g/ml 45 ⁇ /ml 3 ⁇ /ml
  • Virus was harvested 24-48 hours post infection from 10 T175 tissue culture flasks by clarifying media (1,000 x g for 10 minutes) of influenza infected MDCK cells. The virus was pelleted from the media at 100,000 x g for 1 hour. The resulting viral pellet was resuspended in 1 ml phosphate buffered saline (PBS) pH 7.4 and centrifuged through a 20 ml 20-60% (w/v) sucrose gradient in PBS. The influenza virus band was harvested from the 40-45% sucrose region of the gradient, diluted with PBS and pelleted at 100,000 x g. The purified virus pellet was resuspended in 0.5 ml PBS stored at -70°C.
  • PBS phosphate buffered saline
  • Example 2 Cloning of Influenza A/Texas/36/91 HA gene.
  • Viral RNA was extracted as described above from Influenza A/Texas/36/91, obtained from the CDC.
  • the universal primer complementary to the 3' end of influenza RNA segments 5'-AGCAAAAGCAGG-3' (SEQ ID NO. 1) was used with murine Maloney Leukemia Virus (M-MuLV) reverse transcriptase to produced influenza cDNAs.
  • M-MuLV murine Maloney Leukemia Virus
  • Purified viral RNA or mRNA (5 ⁇ g) was used as a template to make cDNA utilizing M-MuLV reverse transcriptase supplied in the First-Strand cDNA Synthesis Kit by Pharmacia Inc.
  • the primer used for cDNA of viral RNA from influenza A strains was a synthetic oligonucleotide primer (5'-AGCAAAAGCAGG-3') (SEQ ID NO. 1), which is homologous to the 3' end of all HA gene virion segments.
  • Amplification of HA genes from cDNA was done by polymerase chain reaction (PCR) using standard reaction conditions (Gene Amp kits; Cetus/Perkin Elmer, Norwalk, CT).
  • the PCR reaction mixture (100 ⁇ l) contained 20 pmol of primers specific for 5' and 3' ends of the HA gene of influenza A (H3) or A (H1) or influenza B strains as determined by consensus sequences found in GenBank DNA data files, as shown in Table 2.
  • Amplification was carried out for 30 cycles with each cycle consisting of 1 minute of denaturation at 94°C, 2 minutes at 55°C for reanealing and 3 minutes at 72°C for extension.
  • the PCR products were analyzed on 0.8% agarose gels for correct size before cloning.
  • PCR primers from the 5' end of the HA gene 5'-GGG GGT ACC CCC GGG AGC AAA AGC AGG GGA AAA TAA AAA-3' (SEQ ID NO. 2) and 3' end of the HA gene: 5'-GA AAC GTC ACG TCT TAT ACG/T TAG/T ACT CCA TGG CCC-3' (SEQ ID NO. 3) were used in the PCR to yield the full length HA gene.
  • a new 5' PCR primer was designed from the 5' end of the gene: 5' end minus signal sequence: 5'-GGG GGT ACC CCC GGG GAC ACA ATA TGT ATA GGC TAC CAT-3' (SEQ ID NO. 4) and the 3' end of the gene: 5'-GA AAC GTC ACG TCT TAT ACG/T TAG/T ACT CCA TGG CCC-3' (SEQ ID NO. 5). These were used in PCR to yield the HA gene minus the signal peptide sequence. This was then inserted into the TA vector cleaved with Kpn I.
  • the 61K signal peptide for baculovirus expression and the polyhedrin promoter were then inserted into the TA vector containing the HA gene minus influenza signal peptide sequence.
  • the resulting baculovirus recombination vector contains the polyhedrin promoter, 61K baculovirus signal peptide, and HA gene for Influenza A/Texas/36/91.
  • HA genes from influenza B strains were cloned from total messenger RNA (mRNA) extracted from MDCK cells infected with the influenza B-strain B/Panama/45/90.
  • Total RNA was prepared from 5 T175 flasks of infected cells. The harvested cells were lysed in the presence of guanidinium thiocyanate and total cell RNA was purified as described above.
  • Total mRNA was extracted from cellular RNA using Oligo-(dT)-cellulose spun columns as described above.
  • the primer used for mRNA from influenza B strains was a random oligonucleotide DNA primer (Pharmacia, Inc.). Table 2.
  • Primers Used for PCR Amplification A/Beijing/32/93 5' end gene (SEQ ID NO. 27) 5' GGG GGA TCC GGT ACC AGC AAA AGC AGG GGA TAA TTC TAT 3' BamH1 Kpn1 5' end minus HA signal peptide(SEQ ID NO. 28) 5' GGG GGT ACC CCC GGG GAC TTT CCA GGA AAT GAC AAC AG 3' Kpn1 Sma1 3' end (SEQ ID NO.
  • cDNA synthesis products used influenza virus A/Texas/36/91 viral RNA as a template.
  • the location of the cDNA segments that code for the influenza proteins could be determined as follows. Purified viral RNA was combined in the reaction mixture with the universal single stranded DNA primer 5'-AGCAAAAGCAGG-3' (SEQ ID NO. 1). This primer is complementary to the 3' end of influenza virion segments, as described above.
  • the reaction also contained the addition of [ ⁇ - 32 P]dCTP to visualize the cDNA products which were separated on 1.5% alkaline hydrolysis gel (Maniatis, et al, 1982) and exposed to X-OMAT-AR film.
  • the PCR ampilfied rHA genes were cloned into a pUC-like plasmid vector using the TA Cloning System (Invitrogen, Inc.). The presence of HA genes were verified by restriction enzyme digest analysis of plasmid DNA purified by standard procedures (Maniatis, et al, 1982). The 5' end of the rHA genes were then analyzed by DNA sequencing and new primers were designed to remove the sequences coding for the hydrophobic signal peptides at the N-terminus HA proteins. The specific 5' and 3' oligonucleotide primers listed in Table 2 were then used to amplify cDNA products by PCR and cloned into E . coli TA plasmid vectors (Invitrogen, Inc.) using standard cloning methods. The resulting DNA clones contained coding sequences for the mature HAs.
  • the rHA genes from A/Texas/36/91, A/Beijing/353/89, A/Beijing/32/92, and B/Panama/45/90 were subcloned by standard procedures (Maniatis et al, 1982) into baculovirus expression vectors.
  • the HA genes were removed from the TA cloning plasmids with the appropriate restriction enzymes and the purified HA DNA fragment inserted into a baculovirus recombination plasmid.
  • the resulting bacterial clones were screened for ampicillin resistance and then cut with restriction enzymes to release the inserted HA gene to confirm is presence.
  • the recombination plasmids containing HA genes were purified on cesium chloride-ethidium bromide gradients (Maniatis, et al, 1982). The 5' end of the plasmids were sequenced to determine the presence of the correct baculovirus signals (AcNPV polyhedrin promoter, ATG translational start signal and baculovirus signal peptide sequence) and proper HA coding sequence in the correct reading frame.
  • the DNA sequences at the 5' end of the HA genes and flanking AcNPV polyhedrin promoter and baculovirus signal peptide are shown as SEQUENCE LISTINGS.
  • SEQ ID NO. 6 encodes the 5' end sequence of the HA gene for A/Beijing/32/92 (sequence range 1-481).
  • SEQ ID NO. 7 is the corresponding amino acid sequence (beginning at the start codon "ATG” [nucleotide 19] of SEQ ID NO. 6).
  • the amino acid sequence of the 61 K signal peptide is set forth in SEQ ID NO. 7 as amino acids 1-18.
  • SEQ ID NO. 8 encodes the 5' end sequence of the HA gene for A/Texas/36/91 (sequence range 1-481)
  • SEQ ID NO. 9 is the corresponding amino acid sequence (beginning at the start codon "ATG” [nucleotide 19] of SEQ ID NO. 8).
  • the amino acid sequence of the 61K signal peptide is set forth in SEQ ID NO.9 as amino acids 1-18.
  • SEQ ID NO. 10 encodes the 5'end sequence of the HA gene for B/Panama/45/90 (sequence range 1-434).
  • SEQ ID NO. 11 is the corresponding amino acid sequence (beginning at the start codon "ATG” [nucleotide 21] of SEQ ID NO. 10).
  • the amino acid sequence of the 61K signal peptide is set forth in SEQ ID NO. 11 as amino acids 1-18.
  • nucleotides 1-10 are the 3' end of the polyhedrin promoter, nucleotides 19-72 encode the 61K signal peptide, and nucleotides 73 to the end encode the 5' end of the HA gene.
  • nucleotides 1-20 are the 3' end of the polyhedrin promoter, nucleotides 21-74 encode the 61K signal peptide, and nucleotides 73 to the end encode the 5' end of the HA gene.
  • Example 4 Expression of Recombinant HA in insect cells.
  • the chimeric recombination plasmids containing cloned HA genes were purified and 2 ⁇ g was mixed with 1 ⁇ g AcNPV wild type DNA.
  • the DNAs were co-precipitated with calcium and transfected into S. frugiperda cells using standard procedures ( Smith, Summers, and Fraser, Mol, and Cell. Biol. 3:2156-2155 (1983 )).
  • Recombinant baculoviruses were identified on the basis of plaque morphology then further purified by additional rounds of plaque-purification. Plaque-purified recombinant baculoviruses are screened for expression of rHA and a single baculovirus expression vector was selected for further development.
  • S. frugiperda cells were infected with a baculovirus vector containing the HA gene from the influenza strain: B/Panama/45/90. At 24, 48, and 72 hours post infection, 1 X 10 6 cells were pulsed with 25 ⁇ Cl [ 35 S]methionine for 15 minutes to label proteins being synthesized. The cells were collected and the proteins separated on an 11% polyacrylamide gel in the presence of 0.1% SDS. The radiolabeled proteins were detected by exposure to X-OMAT-AR film. The location of protein standards and their size in kilodaltons (kd) indicated that the 85 kd recombinant HA protein is one of the major proteins being synthesized in the cells at 48 hours and 72 hours post infection.
  • kd kilodaltons
  • the baculovirus expression vector A8611 which contains the gene for influenza A/Beijing/353/89. produced essentially as described above for A/Beijing/32/92 hemagglutinin under the control of the polyhedrin promoter, was used to infect S. frugiperda cells. Cells were grown at 27°C to a density of 1 x 10 5 cells/ml. In TNMFH media (Gibco BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum, and infected at a multiplicity of infection (MOI) of 1 with the A8611 recombinant baculovirus.
  • MOI multiplicity of infection
  • influenza A/Beijing/353/89 hemagglutinin is produced under the transcriptional control of the baculovirus polyhedrin promoter.
  • Cells are harvested 72 hours post-infection by centrifugation for 15 minutes at 3,400 x g, and washed by resuspension in serum-free TNMFH media followed by centrifugation for 30 minutes at 10,400 x g. The supernatant is decanted, and infected cell pellets are stored at -70°C.
  • 0.5 L of culture (approximately 5 x 10 8 cells) was disrupted for 2 minutes in 40 mL of ice-cold 30 mM Tris-HCL, pH 8.4, 25 mM LiCl, 1% (v/v) Tween-20, 1 mg/mL leupeptin, using a Polytron TM homogenizer (Brinkmann Instruments Inc. Westbury, NY). The homogenate was centrifuged for 30 minutes at 9,200 x g. The supernatant was discarded, and the pellet collected. This step removes soluble and peripheral membrane proteins from the insect cells without extraction of integral membrane proteins like rHA.
  • the pellet was homogenized for 2 minutes at a setting of 4 in 40 mL of ice-cold 30 mM Tris, 10 mM ethanolamine, pH 11, 25 mM LiCl, 2% Tween-20. After a 60 minute incubation on ice, the pH of the homogenate was adjusted to 8.4 with 1 N HCl, and insoluble material was removed by centrifugation for 30 minutes at 9,200 x g. The supernatant containing the soluble rHA was decanted, and the pH was checked and, if necessary, adjusted to 8.4 at room temperature. The insoluble material was resuspended in 40 mL of water for analysis. The HA integral membrane protein was solubilized under the high pH, Tween-20 detergent conditions and remains in solution after the pH is dropped.
  • Proteins were analyzed by SDS polyacrylamide gel electrophoresis. Samples were disrupted in a boiling water bath for 10 minutes in the presence of 2% sodium dodecyl sulfate (SDS) and 5% betamercaptoethanol, then electrophoresed on an 11% polyacrylamide gel in the presence of 0.1% SDS, then stained with Coomassie blue.
  • SDS sodium dodecyl sulfate
  • betamercaptoethanol betamercaptoethanol
  • a chromatography purification process was developed to purify recombinant HA which results in a highly purified recombinant HA antigen that is non-denatured and suitable as a component of an influenza vaccine for human use.
  • the following procedure was used to purify the A/Beijing/353/89 HA from S. frugiperda cells infected with the recombinant virus A8611.
  • the chromatography gel matrices used to purify HA from 0.5 L of infected S. frugiperda cells were 30 mL Pharmacia DEAE Sepharose Fast Flow (in a Pharmacia C16/20 column) and a 4 mL Pharmacia Lentil Lectin Sepharose 4B (in a Pharmacia C10/10 column).
  • the outlet of the DEAE column is connected to the inlet of the lentil lectin column, and the S/N 2 cell extract prepared as described above was applied to the coupled columns at a flow rate of 1 mL/minute.
  • the columns were washed with 30 mM Tris-HCl, pH 8.4, 25 mM LiCl, 0.5% Tween-20 until the UV absorption at 280 nm of the lentil lectin effluent returns to baseline. Under these conditions most of the contaminating proteins bind to DEAE but recombinant HA flows through the column. The remaining contaminants pass through the lectin column and glycosylated rHA binds to the lentil lectin affinity matrix. The DEAE column is disconnected, and the lectin column is washed with another 40 mL of 30 mM Tris-HCl, pH 8.4, 25 mM LiCl, 0.5% Tween-20.
  • the lectin column is washed with 40 mL of 30 mM Tris-HCl, pH 8.4, 25 mM LiCl, 0.4% (v/v) sodium deoxycholate (DOC).
  • This step replaces the Tween-20 detergent with a detergent, like DOC, that can be removed from the protein by dialysis.
  • Recombinant HA is then eluted from the lectin column with approximately 20 mL of 40 mL of 30 mM Tris-HCl, pH 8.4, 25 mM LiCl, 0.4% (v/v) sodium deoxycholate containing 0.3 M a-D-methyl mannoside. Results are analyzed by 11% PAGE.
  • the details of the above purification process may vary with each unique recombinant HA protein.
  • the rHA may bind to the DEAE ion exchange column instead of flowing through. Should this occur, the rHA would be removed from the DEAE column with by washing the column with buffer containing higher concentration of LiCl, NaCl, or other salts.
  • the eluate from the lectin column containing the purified rHA was dialyzed against phosphate buffered saline, pH 7.5 (PBS).
  • the purified recombinant HA was at least 95% pure as determined by analysis on SDS polyacrylamide gels.
  • HA assembles into trimeric structures which are resistant to a variety of proteases, including trypsin, that degrade HA monomers (Murphy and Webster, 1990). Resistance to trypsin treatment can therefore be used as an assay for functional trimer formation. The following procedure was used to study resistance of rHA to protease treatment.
  • Example 7 Immunogenicity of rHA using standardized Mouse Potency Assay.
  • mice potency assay One approach to measure immunogenicity of an antigen is to determine the quantity necessary to induce a detectable antibody response in mice (mouse potency assay).
  • a standardized mouse potency assay is used to measure the immunogenicity of rHA0 vaccine.
  • Groups of 5-10 mice are immunized once with vaccine containing serial dilutions of rHA, i.e., 0.500 ⁇ g, 0.1 ⁇ g, 0.02 ⁇ g, and 0.004 ⁇ g purified rHA.
  • Sera are collected 28 days post immunization and antibodies against the rHA antigen measured in a standard enzyme-linked immunological solid-phase assay (ELISA) in 96 well microtiter plates.
  • ELISA enzyme-linked immunological solid-phase assay
  • a mouse has seroconverted if the OD450 at a 1:100 dilution of the 28 day antisera is greater than three standard deviations above the mean of the OD450 of mouse pre-immune sera.
  • the effective dosage of vaccine needed to seroconvert 50% of the mice is a measure of the immunogenicity of the antigen.
  • mice are immunized once with either 0.1 ⁇ g, 0.02 ⁇ g, 0.004 ⁇ g, or 0.0008 ⁇ g (5-fold dilutions) of rHA0 vaccine.
  • Sera are collected 28 days post immunization and measured against each rHA0 antigen in the vaccine for seroconversion in an ELISA assay.
  • the dosage needed to seroconvert 50% of the mice (ED 50 ) is calculated and a minimum ED 50 established for each rHA0 antigen.
  • Example 8 Administration of rHA in combination with an Adjuvant and comparison with available influenza vaccines.
  • the mouse potency of purified rHA from influenza A/Beijing/353/89 was tested with alum or without alum (neat) and compared to a commercial influenza vaccine, FLUZONE ® (Connaught Laboratories, Inc. Swiftwater, PA) which contains the A/Beijing/353/89 strain of influenza.
  • Vaccine was administered in a dosage of 0.5 ⁇ g, 0.1 ⁇ g, 0.02 ⁇ g, and 0.04 ⁇ g.
  • the mice were boosted at day 28 with the doses of purified rHA described above.
  • sera were collected and titered in an ELISA assay for IgG anti-HA antibodies.
  • Hemagglutination inhibition (HAI) antibodies bind to three of four known epitopes on hemagglutinin and block the ability of influenza to agglutinate red blood cells ( Wilson et al, "Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3A* resolution". Nature, 289:366-378 (1981 )). These antigenic determinants are clustered around the sialic acid receptor binding site on hemagglutinin trimers. Antibodies against these sites will neutralize virus infectivity ( Weis, et al., "Structure of the influenza virus hemagglutinin complexed with its receptor, sialic acid", Nature 333:426-431 (1988 )). The titer and specificity of HAI antibodies are an important measure of the potential for an influenza vaccine to protect against infection with like and related strains of influenza.
  • mice Studies were conducted in mice comparing the ability of purified rHA0 from A/Beijing/353/89 and FLUZONE ® (Connaught Laboratories, Inc., Swiftwater, PA) to elicit HAI antibodies. Groups of 5 mice were injected on days 0 and 28 with 0.5 ⁇ g, 0.1 ⁇ g, 0.02 ⁇ g, or 0.004 ⁇ g of rHA0 or three times these quantities of FLUZONE ® hemagglutinin so that equal levels of recombinant or viral A/Beijing/353/89 hemagglutinin were administered.
  • mice in the highest dose group were immunized with 1.5 ⁇ g of FLUZONE ® hemagglutinin (0.5 ⁇ g of hemagglutinin from each strain) and 0.5 ⁇ g rHA0.
  • FLUZONE ® hemagglutinin 0.5 ⁇ g of hemagglutinin from each strain
  • rHA0 0.5 ⁇ g rHA0
  • Anti-hemagglutinin antibodies were measured in a standard dilutional ELISA against purified rHA0.
  • HAI antibodies were measured against 4 hemagglutinin units of the following antigens: whole influenza A/Beijing/353/89 virus (A/Bei), purified rHA0 A/Beijing/353/89 antigen, and FLUZONE ®
  • the HAI titer is the reciprocal of the highest dilution of antisera which inhibits the agglutination of chicken red blood cells by 50%.
  • Table 3 summarizes serum hemagglutinin IgG and HAI titers in the mice at day 42.
  • High levels of anti-hemagglutinin antibodies were produced with the recombinant rHA0 vaccine. These were about ten fold higher titers than FLUZONE ® .
  • Most significant is that the rHA0 vaccine produced good titers of antibodies that block agglutination of red blood cells by the A/Beijing/353/89 virus and rHA0 antigens.
  • the rHA0 vaccine produced HAI antibodies that recognized equally well the immunogen and the influenza A/Beijing virus.
  • the lower HAI titers against FLUZONE ® may be due to the inability of the antisera to block agglutination by the other two strains of hemagglutinin in the FLUZONE ® vaccine.
  • FLUZONE ® immunized mice produce high HAI antibodies when measured only against itself.
  • the HAI titers against influenza A/Beijing/353/89 virus and the rHA0 antigen were considerably reduced. Similar patterns were observed in the mice in the lower dose groups. Table 3.
  • influenza A/Beijing/353/89 strain in FLUZONE ® shows that there are genetic differences between the influenza A/Beijing/353/89 strain in FLUZONE ® and this same strain of influenza obtained from the FDA and passaged once in eggs prior to using the HAI assay.
  • the fact that antibodies produced in response to the recombinant HA0 cloned from influenza A/Beijing/353/89 blocks agglutination of red blood cells by this strain of influenza as well as itself is good evidence that there were no genetic changes during the cloning process that effected the sialic acid receptor binding site on the purified rHA0 antigen.
  • Example 10 Formulation and Clinical Efficacy of a 1993/1994 Influenza Vaccine.
  • the recombinant HA vaccines used in this study contained full length uncleaved HA (HA0) glycoprotein from the influenza A/Beijing/32/92 (H3N2) virus.
  • Recombinant HA0 (rHA0) was produced in cultures of Lepidopteran (insect) cells following exposure to a baculovirus vector containing cDNA inserts encoding the HA gene.
  • the expressed protein was purified under non-denaturing conditions to >95%, as measured by quantitative scanning densitometry of the bulk antigen electrophoresed on sodium dodecyl sulfate-polyacrylamide gels.
  • the identity of the peptide was confirmed by amino acid analysis, N-terminal sequencing and Western blot analysis with antiinfluenza A/Beijing/32/92 sera.
  • the rHA0 vaccines contained a specified amount of the synthetic HA antigen either dissolved in a phosphate-buffered saline solution or adsorbed to aluminum phosphate (alum) adjuvant in the form of a gel suspension.
  • the licensed trivalent subvirion vaccine used in this study contained 15 ⁇ g/dose of each the HAs from influenza A/Texas/36/91 (N1N1), A/Beijing/32/92 (H3N2) and B/Panama,45/90 viruses (FLUZONE TM attenuated flu vaccine produced in eggs, Connaught Laboratories, Swiftwater, PA).
  • the first 25 subjects to be vaccinated were randomized (i.e., 5 persons per study arm) independently of the other subjects and closely monitored by phone contact for 48 hours post-vaccination before proceeding with the remaining vaccinations. All subjects were instructed to fill out a daily report card of adverse reactions, including both local and systemic symptoms, during the first 6 days post-vaccination. Symptoms were self-graded as mild, moderate or severe in nature. Oral temperatures were taken and recorded by participants if they felt feverish. If present, localized swelling or erythema at the injection site was graded according to whether the area was less than or greater than the size of a quarter in diameter, respectively.
  • influenza-like illness was defined as the presence of any respiratory symptom(s) of two days or greater duration accompanied by fever and/or systemic symptoms of myalgias or chills.
  • Subjects who reported influenza-like symptoms had nasal and pharyngeal swabs obtained for virus culture and identification. Clinical specimens were given coded identification numbers and processed in a blinded fashion.
  • HAI Hemagglutination inhibition
  • Serum HA-specific immunoglobulin G (IgG) antibodies were measured by enzyme-linked immunosorbent assay (ELISA), using purified rHA0 from influenza A/Beijing/32/92 (H3N2) as the coating antigen.
  • the sequence of reagents from solid phase outward consisted of (1) purified rHA0 antigen, (2) serum specimen, (3) alkaline phosphatase-conjugated goat anti-human IgG, and (4) p-nitrophenyl phosphate disodium substrate.
  • the ELISA titer was expressed as the highest dilution at which the optical density of the antigen-containing well was at least twice that of the corresponding control well without antigen.
  • Neutralizing antibodies were measured using the microneutralization assay previously described by Treanor, J.J., and Betts, R.F., J. Infect. Dis. 168:455-459 (1993 ).
  • serial dilutions of heat-inactivated sera were mixed with approximately 100 TCID 50 of influenza A/Beijing/32/92 (H3N2) virus and incubated at 37°C for 1 hr.
  • the virus-sera mixture was then adsorbed to confluent monolayers of Madin-Darby canine kidney (MDCK) cells in 96-well plates for 1 hr at room temperature.
  • MDCK Madin-Darby canine kidney
  • the plates were washed to remove residual inoculum, refed serum-free Dulbecco's MEM with 2 ⁇ g/ml trypsin, and incubated in 5% CO 2 at 33°C for 72 hr. Cells were then fixed with methanol, and viral replication was assessed using a panel of murine monoclonal antibodies specific for the matrix and nucleoproteins of influenza A virus (Centers for Disease Control, Atlanta, GA), followed by alkaline phosphatase-conjugated anti-mouse IgG. The endpoint titer of the sera was defined as the highest dilution resulting in greater than 50% reduction in signal compared with nonneutralized control wells.
  • Virology Viral cultures of nasopharyngeal swab specimens were performed at each institution by standard techniques Specimens were inoculated in either MDCK or rhesus monkey kidney cells and incubated at 33°C for 14 days. Hemadsorption of cell monolayers was tested with 0.4% guinea pig erythrocytes. Influenza viruses were identified in hemadsorption positive cultures by HAI using H3-specific antisera (Centers for Disease Control).
  • Reciprocal HAI, ELISA IgG and neutralizing antibody titers were logarithmically transformed for statistical analysis.
  • a significant response to vaccination was defined as a fourfold or greater rise in antibody titer between the pre-vaccination and 3-week post-vaccination serum specimens.
  • Laboratory evidence of influenza A (H3N2) virus infection was defined as the isolation of virus from nasopharyngeal secretions and/or a four-fold or greater increase in serum HAI antibody titer between the 3-week post-vaccination (preseason) specimen collected in December and the corresponding postseason specimen collected the following spring.
  • the rHA0 vaccines used in this study were safe and well-tolerated. The frequency of adverse reactions did not appear to be influenced by changing the dose of rHA0 antigen from 15 ⁇ g to 90 ⁇ g, but may have been slightly increased by the addition of alum. Localized erythema, pain and tenderness at the injection site were each reported significantly more frequently by recipients of licensed subvirion vaccine than by recipients of either 15 ⁇ g or 90 ⁇ g rHA0 in saline. With the exception of one individual who experienced moderately severe pain, tenderness and stiffness in the arm following immunization with licensed vaccine, all symptoms were graded as mild in nature and were generally 1-2 days in duration. Localized erythema and/or induration, when present, was invariably less than the area of a quarter in size.
  • H3N2 influenza A virus isolated from nasopharyngeal cultures.
  • Significant increases in HAI antibody titer to influenza A/Beijing/32/92 (H3N2) between preseason and postseason serum specimens were also present in three of the four culture-confirmed cases, but not in any other individuals who reported illness.
  • the lone rHA0 recipient who subsequently developed laboratory-confirmed influenza illness had the positive culture obtained 31 days after immunization, and had seroconverted from a prevaccination HAI titer of less than 1:4 to a post-vaccination (preseason) titer of 1:32.
  • Two additional placebo recipients and one volunteer immunized with licensed vaccine had serologic evidence of infection with influenza A (H3N2) virus during the epidemic season in the absence of clinical illness.
  • H3N2 laboratory-confirmed influenza A
  • p ⁇ .05 or infection (p ⁇ .005).
  • influenza vaccines containing purified rHA0 antigen are well-tolerated and capable of eliciting protective immune responses in human subjects. Even at a dose of 90 ⁇ g, the rHA0 evaluated in this study was no more reactogenic than saline placebo, and caused significantly fewer local adverse reactions than did a licensed trivalent subvirion vaccine containing half as much (i.e., 45 ⁇ g) total HA antigen.
  • HA-specific antibody responses to the 15 ⁇ g rHA0 preparation were comparable to those elicited by subvirion vaccine, and were significantly improved by raising the dose of rHA0 to 90 ⁇ g.
  • Example 11 Method for making an improved HAO cloning vector.
  • HA was cloned into Smal or Kpn 1 sites immediately downstream from the chitinase signal peptide.
  • the nucleic and amino acid sequences are shown respectively as SEQ ID NO. 22 and SEQ ID NO. 23:
  • Plasmid pMGS27 was linearized with Pst 1 cut (residues 6-35 of SEQ ID NO. 24 shown): then treating the linear pMGS27 with T4 DNA polymerase plus dATP to create single stranded tails as shown below (residues 23-36 and complement of residues 6-18 of SEQ ID NO. 24):
  • Target HA Gene was Cloned into pMGS27 Step 1. PCR primers were synthesized. Forward oligo (SEQ ID NO. 25): 5' GTC GCC GTG TCC AAC GCG (5' end 20 bases of the mature HA)
  • Reverse oligo (complement of SEQ ID NO. 26): (3' end 20 bases of the mature HA) ATT AA CCGGTCTCTCCGG 5'
  • Linear pMGS27 and the T4 DNA polymerase treated PCR fragment of the HA gene were mixed. The two molecules anneal to each other, to form a circular plasmid which is ready to be used for transforming E. coli.
  • the diagram includes SEQ ID NOS. 25 and 26, residues 23-36 and 6-18 of SEQ ID NO. 24.
  • Example 12 Preparation and efficacy of a Trivalent Types A and B 1995-1996 Influenza Virus Vaccine.
  • H1N1 A/Texas/36/92 ⁇ 1 (H1N1), A/Johanesburg/33/94 (H3N2), and B/Harbin/7/94
  • HA hemagglutinin antigens
  • the HA genes were cloned from the Center for Disease Control/Food and Drug Administration recommended strains of influenza A and B viruses as described above and the identity of each cloned gene determined by DNA sequence analysis.
  • Baculovirus expression vectors containing the cloned HA genes from influenza virus strains A/Texas/36/91 (H1N1), A/Johanesburg/33/94 (H3N2), B/Harbin/7/94 were used to produce the recombinant HA antigens in cultured insect cells.
  • the recombinant HA proteins are full length, uncleaved hemagglutinins (rHAO) with a molecular weight of approximately 69,000.
  • the rHAO were produced in a Spodoptera frugiperda (Lepidopteran) cell line maintained in a serum-free culture medium.
  • the trivalent vaccines is composed of purified (greater than 95% pure, more probably greater than 99% pure) rHAO from the two influenza A strains and one B strain mixed in equal proportions.
  • the vaccine is supplied for clinical use as purified types A and B rHAO proteins in phosphate buffered saline solution without added preservative.
  • mice Animal studies with monovalent, bivalent and trivalent rHAO vaccines have demonstrated that they are free of significant toxicity. There are no detectable toxic or adventitious agents in the vaccine.
  • mice a single immunization with 15 micrograms of rHAO antigens without adjuvant induces in two to three weeks high levels of anti-HA IgG antibodies, hemagglutinin inhibition (HAI) antibodies and neutralizing antibodies.
  • HAI hemagglutinin inhibition
  • mice were immunized with 15 micrograms of purified rHAO A/Beijing/32/92 (H3N2) made in cells adapted to media containing 10% fetal bovine serum or rHAO made in insect cells adapted to media containing 10% fetal bovine serum or rHAO made in insect cells adapted to a serum-free medium (rHAO-SF).
  • H3N2 purified rHAO A/Beijing/32/92
  • rHAO-SF serum-free medium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Claims (12)

  1. Procédé de fabrication de la protéine de fusion de l'hémagglutinine, ledit procédé comprenant l'infection de cellules d'insectes cultivées avec un vecteur contenant les séquences suivantes dans l'ordre 5' → 3' : un promoteur polyèdre provenant d'un baculovirus, un codon de départ de la traduction ATG, une séquence codante pour un peptide signal de chitinase, la séquence codante pour l'hémagglutinine provenant d'une souche grippale choisie dans le groupe comprenant une souche grippale A et une souche grippale B, la séquence codante pour la seconde protéine, un codon de terminaison de la traduction, et un signal de polyadénylation d'ARN polyèdre, et la culture des cellules dans un milieu nutritif, où le peptide signal de chitinase comprend les acides aminés TRP LEU VAL ALA VAL SER ASN ALA ou la séquence codante du peptide signal de chitinase comprend les nucléotides TGG TTG GTC GCC GTT TCT AAC GCG.
  2. Procédé selon la revendication 1, comprenant en outre l'isolement de la protéine de fusion de l'hémagglutinine grippale à partir des cellules jusqu'à une pureté d'au moins 95 %.
  3. Procédé selon la revendication 2, dans lequel une protéine de fusion de l'hémagglutinine glycosylée mature est isolée par séparation des protéines liées à la membrane y compris la protéine de fusion de l'hémagglutinine glycosylée mature des protéines non membranaires à un pH alcalin, lavage des protéines liées à la membrane pour éluer la protéine de fusion de l'hémagglutinine glycosylée mature, séparation de la protéine de fusion de l'hémagglutinine glycosylée mature par une résine échangeuse d'anions avec un changement de pH, et séparation de la protéine de fusion de l'hémagglutinine glycosylée mature soumise à l'échange d'anions par une résine échangeuse de cations avec un changement de la concentration en sel.
  4. Procédé de fabrication d'un vecteur contenant les séquences 5' → 3' suivantes : un promoteur polyèdre provenant d'un baculovirus, un codon de départ de la traduction ATG, une séquence codante pour un peptide signal de chitinase, les séquences codantes pour l'hémagglutinine provenant d'une souche grippale choisie dans le groupe comprenant les souches grippales A et les souches grippales B, un codon de terminaison de la traduction, et un signal de polyadénylation d'ARN polyèdre comprenant la récolte du virus à partir du milieu cellulaire et l'isolement soit de l'ARN viral, pour les souches grippales A, soit de l'ARNm, pour les souches grippales B ;
    la synthèse de l'ADNc en utilisant soit une amorce universelle (5'-AGCAAAAGCAGG-3' (SEQ ID NO : 1) pour l'ARN viral provenant des souches grippales A soit des amorces aléatoires pour l'ARNm provenant des souches grippales B, où les amorces en 5' et 3' ont des sites d'enzymes de restriction aux extrémités que l'on ne trouve pas au sein des gènes de l'hémagglutinine ;
    l'amplification des amorces grippales A ou B et de l'ADNc grippal mélangés avec les segments des gènes de l'hémagglutinine pour produire des fragments d'ADN double brin contenant les séquences codantes entières de l'hémagglutinine mature ;
    l'identification du peptide signal des gènes de l'hémagglutinine puis l'amplification des gènes de l'hémagglutinine moins le peptide signal ; et
    le clonage des gènes de l'hémagglutinine moins le peptide signal dans un vecteur contenant le promoteur polyèdre de l'AcNPV et la séquence codante pour le peptide signal de chitinase, le peptide signal de chitinase comprenant les acides aminés TRP LEU VAL ALA VAL SER ASN ALA ou la séquence codante du peptide signal de chitinase comprend les nucléotides TGG TTG GTC GCC GTT TCT AAC GCG.
  5. Procédé selon la revendication 4, dans lequel les gènes de l'hémagglutinine sont clonés dans le vecteur en utilisant une PCR de telle manière que le vecteur code le peptide signal couplé directement à l'hémagglutinine sans aucun acide aminé intervenant.
  6. Procédé selon la revendication 4, comprenant en outre la transfection du vecteur dans des cellules d'insectes, et la sélection des cellules pour l'expression de l'hémagglutinine.
  7. Protéine de fusion de l'hémagglutinine grippale recombinante exprimée dans un système d'expression de baculovirus cultivé dans des cellules d'insectes, pouvant être obtenue par le procédé selon l'une quelconque des revendications 1 à 3 et purifiée jusqu'à au moins 95 %.
  8. Composition vaccinale comprenant la protéine de fusion de l'hémagglutinine grippale recombinante selon la revendication 7.
  9. Composition vaccinale selon la revendication 8, dans laquelle la seconde protéine est choisie dans le groupe comprenant la protéine virale de l'hépatite B, une protéine du VIH, un antigène carcinoembryonnaire et une neuraminidase.
  10. Composition vaccinale selon la revendication 8, dans laquelle la souche grippale infecte les êtres humains.
  11. Composition vaccinale selon la revendication 8, comprenant en outre
    (i) un support pharmaceutiquement acceptable, ou
    (ii) un adjuvant, ou
    (iii) un support pharmaceutiquement acceptable et un adjuvant.
  12. Composition vaccinale selon la revendication 11, dans laquelle le support pharmaceutiquement acceptable est un système de délivrance polymère.
EP05076536A 1993-09-13 1995-05-26 Procédé de production de vaccins antigrippaux polyvalents composés d'hemagglutinine Expired - Lifetime EP1605052B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK05076536.1T DK1605052T3 (da) 1993-09-13 1995-05-26 Fremgangsmåde til at producere multivalente influenzahæmaglutininvacciner
EP11159899.1A EP2374894B1 (fr) 1993-09-13 1995-05-26 Procédé pour la production de vaccins polyvalents contre l'hémagglutinine de la grippe

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/120,607 US5762939A (en) 1993-09-13 1993-09-13 Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
PCT/US1995/006750 WO1996037624A1 (fr) 1993-09-13 1995-05-26 Procede de production de vaccins antigrippaux polyvalents composes d'hemagglutinine
EP95922133A EP0833933B1 (fr) 1993-09-13 1995-05-26 Vecteur et procede de production d'hemagglutinine de virus grippaux
CA2222129A CA2222129C (fr) 1993-09-13 1995-05-26 Procede de production de vaccins antigrippaux polyvalents composes d'hemagglutinine
CNB951979280A CN100390289C (zh) 1993-09-13 1995-05-26 生产流感血凝素多价疫苗的方法
LT97-201A LT4461B (lt) 1993-09-13 1997-12-23 Gripo hemagliutinino multivalentinių vakcinų gamybos būdas

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP95922133A Division EP0833933B1 (fr) 1993-09-13 1995-05-26 Vecteur et procede de production d'hemagglutinine de virus grippaux
EP95922133.4 Division 1996-11-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP11159899.1A Division EP2374894B1 (fr) 1993-09-13 1995-05-26 Procédé pour la production de vaccins polyvalents contre l'hémagglutinine de la grippe
EP11159899.1 Division-Into 2011-03-25

Publications (3)

Publication Number Publication Date
EP1605052A2 EP1605052A2 (fr) 2005-12-14
EP1605052A3 EP1605052A3 (fr) 2008-08-13
EP1605052B1 true EP1605052B1 (fr) 2011-07-27

Family

ID=27508642

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05076536A Expired - Lifetime EP1605052B1 (fr) 1993-09-13 1995-05-26 Procédé de production de vaccins antigrippaux polyvalents composés d'hemagglutinine
EP95922133A Expired - Lifetime EP0833933B1 (fr) 1993-09-13 1995-05-26 Vecteur et procede de production d'hemagglutinine de virus grippaux

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP95922133A Expired - Lifetime EP0833933B1 (fr) 1993-09-13 1995-05-26 Vecteur et procede de production d'hemagglutinine de virus grippaux

Country Status (22)

Country Link
US (2) US5762939A (fr)
EP (2) EP1605052B1 (fr)
JP (1) JP3757318B2 (fr)
CN (1) CN100390289C (fr)
AT (2) ATE518000T1 (fr)
AU (1) AU712776B2 (fr)
BR (1) BR9510590A (fr)
CA (1) CA2222129C (fr)
CZ (2) CZ301021B6 (fr)
DE (1) DE69534449T2 (fr)
DK (3) DK0833933T3 (fr)
ES (1) ES2248799T3 (fr)
FI (1) FI974319A (fr)
HK (1) HK1083867A1 (fr)
HU (1) HUT77921A (fr)
IS (1) IS4620A (fr)
LT (1) LT4461B (fr)
NO (1) NO975434L (fr)
NZ (1) NZ288026A (fr)
PT (1) PT1605052E (fr)
SK (1) SK286441B6 (fr)
WO (1) WO1996037624A1 (fr)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387373B1 (en) * 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
EP2374894B1 (fr) * 1993-09-13 2014-09-17 Protein Sciences Corporation Procédé pour la production de vaccins polyvalents contre l'hémagglutinine de la grippe
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
DK1002110T3 (da) * 1997-08-05 2003-05-26 Stressgen Biotechnologies Corp Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6348450B1 (en) * 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US8026096B1 (en) * 1998-10-08 2011-09-27 Protein Sciences Corporation In vivo active erythropoietin produced in insect cells
MXPA01006214A (es) * 1998-12-17 2004-09-06 Aventis Pasteur Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio.
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
AU5926700A (en) 1999-07-08 2001-01-30 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
US6544750B1 (en) 1999-08-17 2003-04-08 Thromgen, Inc. Peptide analogs as selective inhibitors of thrombin activation of protease activated receptor 1
DE19963857A1 (de) * 1999-12-30 2001-07-26 Qiagen Gmbh Primer, insbesondere für Primer-abhängige Nukleinsäure-Syntheseprozesse und Nukleinsäure-Amplifikationsverfahren
KR100919266B1 (ko) * 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
GB0022969D0 (en) * 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
US20040071733A1 (en) * 2001-02-05 2004-04-15 Hiroshi Takaku Baculovirus vector vaccine
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
WO2005018539A2 (fr) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Hemagglutinine du virus de la grippe et variantes de la neuraminidase
AU2004249802B2 (en) * 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
EP1668112A4 (fr) 2003-06-20 2009-04-29 Protein Sciences Corp Vecteurs d'expression d'immunogenes de sras, compositions contenant de tels vecteurs ou leurs produits d'expression, procedes et dosages pour leur production et leur utilisation
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8506967B2 (en) 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US7527967B2 (en) * 2003-11-25 2009-05-05 Academia Sinica Recombinant baculovirus and virus-like particle
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
GB2429207A (en) 2004-02-02 2007-02-21 Ambrx Inc Modified human interferon polypeptides and their uses
US7342107B2 (en) 2004-05-27 2008-03-11 Centocor, Inc. Cynomolgus prostate specific antigen
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
EP1771573A4 (fr) * 2004-07-21 2009-02-18 Ambrx Inc Polypeptides biosynthetiques obtenus a partir d'acides amines codes par voie non naturelle
EP1836298B1 (fr) * 2004-12-22 2012-01-18 Ambrx, Inc. Compositions de synthetase d'aminoacyl-arnt et utilisations correspondantes
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7816320B2 (en) * 2004-12-22 2010-10-19 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
DK1828224T3 (en) 2004-12-22 2016-07-18 Ambrx Inc Compositions containing, methods including, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES
EP1841785A2 (fr) 2005-01-19 2007-10-10 Vaxinnate Corporation Compositions comprenant motifs moleculaires associes a des agents pathogenes et des antigenes et leur utilisation pour stimuler la reponse immunitaire
WO2006091722A2 (fr) * 2005-02-23 2006-08-31 Uab Research Foundation Vaccination amplifiee par alkyle-glycosides
EP2441471B1 (fr) 2005-03-08 2014-10-08 MedImmune, LLC Virus de la grippe réassortis
JP5869744B2 (ja) 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
ATE529442T1 (de) * 2005-06-03 2011-11-15 Ambrx Inc Verbesserte humane interferon-moleküle und ihre verwendungen
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
AU2005335491B2 (en) 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
EP1926780B1 (fr) 2005-09-22 2013-08-14 Medivas, LLC Formules de poly(ester amide) et de poly(ester uréthane) contenant des diesters de bis-( -amino)-diol et méthodes d'emploi
WO2007038246A2 (fr) * 2005-09-22 2007-04-05 Medivas, Llc Compositions polymeres solides pour administration et methodes d'utilisation de celles-ci
US7468187B2 (en) 2005-10-18 2008-12-23 Iowa State University Research Foundation, Inc. Canine influenza virus and related compositions and methods of use
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
US20110180430A1 (en) 2005-11-04 2011-07-28 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2007052155A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
CA2628152C (fr) * 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
DE602006020480D1 (de) * 2005-11-08 2011-04-14 Ambrx Inc Beschleuniger für die modifikation nichtnatürlicher aminosäuren und nichtnatürlicher aminosäurepolypeptide
PT2339014E (pt) * 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
WO2007067744A2 (fr) * 2005-12-07 2007-06-14 Medivas, Llc Procédé destiné à assembler une composition d'administration polymère-agent biologique
EP1968635B1 (fr) * 2005-12-14 2014-09-17 Ambrx, Inc. Compositions contenant des acides aminés et polypeptides non naturels, procédés mettant en jeu ceux-ci et utilisations de ceux-ci
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
US9333249B2 (en) 2006-02-09 2016-05-10 Educational Foundation Jichi Medical University Recombinant baculovirus vaccine
CU23576A1 (es) 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
EP2476432B1 (fr) * 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions incluant de l'hémagglutinine, procédés pour leur fabrication et leurs méthodes d'utilisation
EP2004226A1 (fr) 2006-03-24 2008-12-24 Novartis Vaccines and Diagnostics GmbH & Co. KG Stockage de vaccins antigrippaux sans refrigeration
CA2649672C (fr) * 2006-05-02 2015-07-07 Medivas, Llc Administration d'agents ophtalmiques a l'exterieur et a l'interieur de l'oeil
CN102258778B (zh) * 2006-05-05 2014-08-13 淡马锡生命科学研究院有限公司 生物分子表面展示及其用途
US20070282011A1 (en) * 2006-05-09 2007-12-06 Medivas, Llc Biodegradable water soluble polymers
KR101696727B1 (ko) 2006-07-17 2017-01-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 인플루엔자 백신
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
DK2615108T3 (en) * 2006-09-08 2017-01-30 Ambrx Inc Modified human plasma polypeptide or fc scaffolds and their applications
WO2008030614A2 (fr) * 2006-09-08 2008-03-13 Ambrx, Inc. Transcription d'arnt suppresseur dans des cellules de vertébrés
WO2008030613A2 (fr) * 2006-09-08 2008-03-13 Ambrx, Inc. Arnt suppresseur hybride pour cellules de vertébrés
US20100105025A1 (en) * 2006-10-12 2010-04-29 Engelhard Eric K Devices for generating detectable polymers
US20080124710A1 (en) * 2006-10-12 2008-05-29 Engelhard Eric K Devices for generating detectable polymers
WO2008118487A2 (fr) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions et procédés pour augmenter l'immunogénicité de vaccins à base de glycoprotéine
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
EA201070066A1 (ru) * 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
CA2615372A1 (fr) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Particules semblables au virus grippal a comprenant de l'hemagglutinine
EP2178944A1 (fr) * 2007-07-24 2010-04-28 Medivas, LLC Compositions polymères cationiques biodégradables de transfert de gène et procédés d'utilisation
AU2008326324B9 (en) 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN103122354B (zh) 2007-11-27 2018-03-23 麦迪卡格公司 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp)
EP3103880A1 (fr) 2008-02-08 2016-12-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
ES2594102T3 (es) * 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
WO2010003235A1 (fr) * 2008-07-08 2010-01-14 Medicago Inc. Antigènes de la grippe recombinés solubles
SG192501A1 (en) 2008-07-11 2013-08-30 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
UA118536C2 (uk) * 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
JP2012500207A (ja) * 2008-08-13 2012-01-05 メディバス エルエルシー Ａａｂｂ−ポリ（デプシペプチド）生分解性ポリマー及び使用方法
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
EP3216800A1 (fr) * 2008-09-26 2017-09-13 Ambrx, Inc. Polypeptides d'érythropoïétine animale modifiés et leurs utilisations
DK2396032T3 (en) 2009-02-10 2016-12-19 Seqirus Uk Ltd Influenza vaccines with reduced amounts of squalene
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
CA2763440A1 (fr) 2009-05-29 2010-12-02 Novartis Ag Dosages d'hemagglutinines de virus de la grippe
WO2010144797A2 (fr) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
GB2471093A (en) * 2009-06-17 2010-12-22 Cilian Ag Viral protein expression in ciliates
NZ597401A (en) 2009-06-24 2013-09-27 Medicago Inc Chimeric influenza virus-like particles comprising hemagglutinin
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
WO2011005772A1 (fr) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Procédés pour préparer des vésicules et formulations produites à partir de ces procédés
US8810417B2 (en) * 2009-08-28 2014-08-19 The Invention Science Fund I, Llc Beverage immersate with detection capability
US9024766B2 (en) * 2009-08-28 2015-05-05 The Invention Science Fund, Llc Beverage containers with detection capability
CN102695523A (zh) 2009-09-10 2012-09-26 诺华有限公司 针对呼吸道疾病的组合疫苗
KR20180026562A (ko) 2009-09-22 2018-03-12 메디카고 인코포레이티드 식물-유래 단백질의 제조방법
NZ600363A (en) 2009-12-21 2014-07-25 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
AU2010343095B2 (en) * 2009-12-28 2017-01-05 Sanofi Vaccine Technologies, S.A.S. Production of heterologous polypeptides in microalgae, microalgal extracellular bodies, compositions, and methods of making and uses thereof
EP2519636B8 (fr) * 2009-12-28 2017-08-09 DSM IP Assets B.V. Production de protéine hémagglutinine-neuraminidase dans des microalgues
CN102939101A (zh) * 2010-01-26 2013-02-20 科罗拉多大学董事会，法人 用于通用疫苗的流感病毒组合物和方法
JP2013522231A (ja) * 2010-03-11 2013-06-13 イミューン デザイン コーポレイション インフルエンザのためのワクチン
EP3187585A1 (fr) 2010-03-25 2017-07-05 Oregon Health&Science University Glycoprotéines de cytomégalovirus (cmv) et vecteurs de recombinaison
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
WO2012006367A2 (fr) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions et méthodes pour traiter la grippe
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
BR112013003522B1 (pt) 2010-08-17 2021-05-25 Ambrx, Inc. polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, seu método de preparação e seu uso, bem como ácido nucleico e célula hospedeira
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
US8513006B2 (en) 2010-09-14 2013-08-20 University of Pittsburgh—of the Commonwealth System of Higher Education Tetravalent influenza vaccine and use thereof
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN102023213B (zh) * 2010-09-28 2014-04-02 汕头大学医学院 一种检测流感病毒抗体的荧光微量细胞凝集方法
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
EP3205353B1 (fr) 2011-03-21 2021-01-13 Altimmune Inc. Produit thérapeutique immunologique à action rapide et prolongée
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP3159368A1 (fr) 2011-06-23 2017-04-26 DSM IP Assets B.V. Nouveaux copolymères de polyester-amide biodégradables pour l'administration de médicaments
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
WO2013057715A1 (fr) 2011-10-20 2013-04-25 Novartis Ag Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pédiatrique
EP2586461A1 (fr) 2011-10-27 2013-05-01 Christopher L. Parks Particules virales dérivées d'un virus enveloppé
WO2013072768A2 (fr) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Dérivés synthétiques de mpl et ses utilisations
EP2791680B1 (fr) 2011-12-12 2015-12-09 Novartis AG Analyse pour hémagglutinines du virus de la grippe
CA2894442C (fr) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions et methodes de traitement d'infections virales
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
TWI434933B (zh) * 2012-04-17 2014-04-21 Nat Univ Tsing Hua 抗多型禽流感病毒之ｄｎａ疫苗及其組合物
EP2679596B1 (fr) 2012-06-27 2017-04-12 International Aids Vaccine Initiative Variante de la protéine env du VIH-1
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (fr) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
WO2016179099A1 (fr) * 2015-05-04 2016-11-10 Epivax, Inc. Glycoprotéine hémagluttinine h7 modifiée de la séquence h7 de la grippe a/shanghai/2/2013
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
HUE051783T2 (hu) * 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
BR112018014109A2 (pt) 2016-01-11 2018-12-11 Verndari Inc composições de microagulhas e métodos de uso das mesmas
CN106749554B (zh) * 2017-01-20 2021-01-15 中山大学 一种流感病毒血凝素蛋白的纯化方法
CN110637027A (zh) 2017-02-08 2019-12-31 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
US10874737B2 (en) 2018-06-01 2020-12-29 Iowa State University Research Foundation, Inc. Influenza nanovaccine
MX2023002339A (es) 2020-08-24 2023-03-22 Sanofi Pasteur Inc Vacunas contra infecciones por sars-cov-2.
CA3190375A1 (fr) 2020-08-24 2022-03-03 Natalie ANOSOVA Vaccins contre la covid-19 avec des adjuvants d'emulsion de squalene contenant du tocopherol
CA3233926A1 (fr) 2021-10-08 2023-04-13 Sanofi Pasteur Inc. Vaccins multivalents contre la grippe
CA3237134A1 (fr) 2021-11-05 2023-05-11 Timothy ALEFANTIS Vaccins contre la grippe multivalents comprenant de l'hemagglutinine et de la neuraminidase recombinantes et leurs methodes d'utilisation
AU2022381813A1 (en) 2021-11-05 2024-06-20 Sanofi Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
US20240042021A1 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024077118A2 (fr) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Protéines multispécifiques et procédés associés
CN116763915B (zh) * 2023-08-17 2023-11-03 山东兴瑞生物科技有限公司 一种用于治疗和预防流感病毒的多价疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029763A (en) * 1974-08-05 1977-06-14 Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing purified neuraminidase antigen and method of using the same
IN150740B (fr) * 1978-11-24 1982-12-04 Hoffmann La Roche
US4659669A (en) * 1981-03-02 1987-04-21 Regents Of The Univ. Of California Microbial expression of human influenza hemagglutinin proteins
US4752473A (en) * 1984-10-12 1988-06-21 The Regents Of The University Of California Expression of glycosylated human influenza hemagglutinin proteins
US4920213A (en) * 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
EP0349594A4 (en) * 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
CA2084180A1 (fr) * 1991-12-11 1993-06-12 Paul P. Hung Expression d'immunogenes specifiques a l'aide d'antigenes viraux
AU2517995A (en) * 1994-05-20 1995-12-18 Microgenesys, Inc. Immunogenic carcinoembryonic antigen and methods of use and production

Also Published As

Publication number Publication date
US5762939A (en) 1998-06-09
EP0833933A1 (fr) 1998-04-08
DK1275726T3 (da) 2008-06-23
CN100390289C (zh) 2008-05-28
ES2248799T3 (es) 2006-03-16
CN1194005A (zh) 1998-09-23
CA2222129C (fr) 2010-04-27
NZ288026A (en) 1999-11-29
US5858368A (en) 1999-01-12
LT4461B (lt) 1999-02-25
PT1605052E (pt) 2011-10-19
CZ301021B6 (cs) 2009-10-14
DK0833933T3 (da) 2005-10-10
FI974319A0 (fi) 1997-11-25
IS4620A (is) 1997-11-25
DE69534449D1 (de) 2006-01-26
BR9510590A (pt) 1999-11-30
FI974319A (fi) 1998-01-22
DE69534449T2 (de) 2006-07-06
EP1605052A3 (fr) 2008-08-13
JP3757318B2 (ja) 2006-03-22
ATE304602T1 (de) 2005-09-15
NO975434L (no) 1998-01-19
SK158897A3 (en) 1999-06-11
AU2692595A (en) 1996-12-11
EP0833933B1 (fr) 2005-09-14
ATE518000T1 (de) 2011-08-15
HK1083867A1 (en) 2006-07-14
SK286441B6 (sk) 2008-10-07
CA2222129A1 (fr) 1996-11-28
CZ373897A3 (cs) 1999-02-17
WO1996037624A1 (fr) 1996-11-28
LT97201A (en) 1998-09-25
CZ299862B6 (cs) 2008-12-17
EP1605052A2 (fr) 2005-12-14
AU712776B2 (en) 1999-11-18
DK1605052T3 (da) 2011-11-07
HUT77921A (hu) 1998-10-28
JP2000513922A (ja) 2000-10-24
NO975434D0 (no) 1997-11-26

Similar Documents

Publication Publication Date Title
EP1605052B1 (fr) Procédé de production de vaccins antigrippaux polyvalents composés d'hemagglutinine
US6245532B1 (en) Method for producing influenza hemagglutinin multivalent vaccines
US9180180B2 (en) Functional influenza virus-like particles (VLPs)
US9050290B2 (en) Functional influenza virus like particles (VLPs)
US10544399B2 (en) Highly efficient influenza matrix (M1) proteins
US8513006B2 (en) Tetravalent influenza vaccine and use thereof
EP1275726B1 (fr) Procédé de production de vaccins antigrippaux polyvalents composés d'hémagglutinine
EP2374894B1 (fr) Procédé pour la production de vaccins polyvalents contre l'hémagglutinine de la grippe
AU733191B2 (en) A method for producing influenza hemagglutinin multivalent vaccines
CN101353375A (zh) 生产流感血凝素多价疫苗的方法
KR19990022028A (ko) 인플루엔자 헤마글루티닌 다가 백신의 제조방법

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050712

AC Divisional application: reference to earlier application

Ref document number: 0833933

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HACKETT, CRAIG STANWAY

Inventor name: SMITH, GALE EUGENE

Inventor name: VOZNESENSKY, ANDREI I.

Inventor name: WILKINSON, BETHANIE E.

Inventor name: VOLVOVITZ, FRANKLIN

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083867

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PROTEIN SCIENCES CORPORATION

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090326

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 0833933

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 69536179

Country of ref document: DE

Effective date: 20110922

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20111012

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ARNOLD & SIEDSMA AG

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1083867

Country of ref document: HK

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2370937

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20111223

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20110402475

Country of ref document: GR

Effective date: 20111117

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20120502

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 69536179

Country of ref document: DE

Effective date: 20120502

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20140520

Year of fee payment: 20

Ref country code: IE

Payment date: 20140527

Year of fee payment: 20

Ref country code: GB

Payment date: 20140527

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140529

Year of fee payment: 20

Ref country code: IT

Payment date: 20140526

Year of fee payment: 20

Ref country code: PT

Payment date: 20140520

Year of fee payment: 20

Ref country code: SE

Payment date: 20140530

Year of fee payment: 20

Ref country code: LU

Payment date: 20140604

Year of fee payment: 20

Ref country code: NL

Payment date: 20140526

Year of fee payment: 20

Ref country code: ES

Payment date: 20140526

Year of fee payment: 20

Ref country code: CH

Payment date: 20140527

Year of fee payment: 20

Ref country code: GR

Payment date: 20140529

Year of fee payment: 20

Ref country code: FR

Payment date: 20140519

Year of fee payment: 20

Ref country code: AT

Payment date: 20140521

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20140602

Year of fee payment: 20

Ref country code: BE

Payment date: 20140530

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69536179

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V4

Effective date: 20150526

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20150526

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20150526

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20150525

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 518000

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150526

REG Reference to a national code

Ref country code: GR

Ref legal event code: MA

Ref document number: 20110402475

Country of ref document: GR

Effective date: 20150527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20150525

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20150602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20150526

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20150527